Pfizer Inc. (PFE)
| Market Cap | 157.04B |
| Revenue (ttm) | 58.50B |
| Net Income (ttm) | 2.12B |
| Shares Out | 5.65B |
| EPS (ttm) | 0.37 |
| PE Ratio | 75.16 |
| Forward PE | 12.52 |
| Dividend | $1.68 (6.04%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 45,367,552 |
| Open | 27.86 |
| Previous Close | 27.70 |
| Day's Range | 27.52 - 27.91 |
| 52-Week Range | 25.20 - 40.37 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 36.00 (+29.45%) |
| Earnings Date | May 1, 2024 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $36.0, which is an increase of 29.45% from the latest price.
News
Josh Brown buys more Pfizer
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's Halftime Report' to explain why he's doubling down on Pfizer.
Nussbaum Law Group, P.C. and Roberts Law Firm US, PC Announce A $50 Million Class Action Settlement with Pfizer on Behalf of Direct Purchasers of EpiPen® or Generic EpiPen
NEW YORK--(BUSINESS WIRE)--Nussbaum Law Group, P.C. and Roberts Law Firm US, PC: COURT-ORDERED LEGAL NOTICE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS If you purchased EpiPen® or generi...
Pfizer Stock Gets Boost From Better-Than-Expected Earnings
Pfizer (PFE) shares rose Wednesday after first-quarter earnings and revenue fell less than expected, with the decline partially offset by sales growth in the company's non-COVID-related products.
Pfizer beats revenue estimates - raises profit outlook on cost cuts and strong non-Covid sales
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
The results come as Pfizer tries to regain its footing after the rapid decline of its Covid business.
Pfizer first-quarter results top estimates, drugmaker boosts full-year profit outlook
Pfizer Inc. shares PFE, -0.08% gained 1.5% premarket on Wednesday after the company reported first-quarter profit and sales that beat analyst expectations, boosted by strong sales of its Vyndaqel fami...
Pfizer's 44% Decline In Profits Still Tops Estimates—Stock Bounces From Decade Low
Pfizer comfortably beat expectations in its quarterly earnings report Wednesday morning, as the American pharmaceutical giant attempts to regain its footing as the COVID-19 pandemic subsides.
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty, Paxlovid decline
Pfizer Inc. (NYSE: PFE) has announced its financial outcomes for the first quarter of 2024, displaying strong performance in its non-COVID product portfolio. This includes heightened revenues from rec...
Pfizer beats profit estimates on cost cuts, RSV vaccine sales
Pfizer beat first-quarter profit estimates on Wednesday, benefiting from cost cuts and strong sales for its pneumonia and respiratory synctitial virus vaccines.
Pfizer Reports First-Quarter 2024 Results
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of it...
Pfizer, Genmab get full FDA approval for cervical-cancer drug
Pfizer and Genmab on Monday said they had received full approval from U.S. regulators for their treatment for certain forms of cervical cancer.
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics L...
US FDA grants full approval for Pfizer's cervical cancer drug
The U.S. Food and Drug Administration granted traditional approval for Pfizer's drug for cervical cancer patients with disease progression on or after chemotherapy, the agency said on Monday.
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Mee...
What Factors Will Drive Pfizer's Q1 Performance?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.
Pfizer Receives FDA Approval for Bleeding Disorder Treatment
The treatment, Beqvez, will be available by prescription to eligible patients this quarter.
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
US FDA approves Pfizer's gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a b...
U.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults wit...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1...
Pfizer Declares Second-Quarter 2024 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company's common stock, payable June 14, 2024, to ho...
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
European Commission Approves Pfizer's EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult ...